Join to view full profile
8801 Fast Park DriveSuite 301Raleigh, NC 27617
Phone+1 919-371-8411
Dr. Crater is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Glenn Crater is the Founder of Clinical Pharma Specialist Consultants, and serves as Chief Medical Officer at Innospera Pharma. He is based in Raleigh, NC.
Dr. Crater has authored several publications related to respiratory diseases, with notable works published in journals such as CHEST, Therapeutic Advances in Respiratory Disease, The European Respiratory Journal, BMC Pulmonary Medicine, and Lancet Respiratory Medicine. His research has been widely cited, with a focus on chronic obstructive pulmonary disease (COPD) and related treatments.
Education & Training
University of Tennessee Health Science Center College of MedicineClass of 1993
Certifications & Licensure
NC State Medical License 2005 - 2027
National Board of Physicians and Surgeons Internal Medicine- National Board of Physicians and Surgeons Pulmonary Disease
Publications & Presentations
PubMed
- A double-blind, randomized, placebo-controlled, phase 2 trial examined the efficacy and safety of monlunabant in adults with diabetic kidney disease.David Z I Cherney, Karen Bonefeld, Glenn Crater, Jamie P Dwyer, Ofir Frenkel
Kidney International. 2026-06-01 - 1 citationsMonlunabant in adults with obesity and metabolic syndrome: Open-label extension of a phase 2a trial.Filip K Knop, George Kunos, Dror Dicker, Jean-Sebastien Paquette, Louis Aronne
Diabetes, Obesity & Metabolism. 2026-05-01 - 7 citationsEfficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial.Filip K Knop, George Kunos, Dror Dicker, Jean-Sebastien Paquette, Louis Aronne
The Lancet. Diabetes & Endocrinology. 2025-11-01
Press Mentions
Inversago Pharma Initiates a Phase 1 Clinical Trial on INV-202, a Next Generation Peripherally-Acting CB1 BlockerSeptember 7th, 2021- Inversago Pharma Presents Data from Phase 1b Trial of INV-202, a Peripheral CB1r Blocker for Metabolic Syndrome, at the 83rd American Diabetes Association Scientific SessionsJune 25th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
